 Connection
Andrew Kwilasz to Naltrexone
This is a "connection" page, showing publications Andrew Kwilasz has written about Naltrexone.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.878 |
|
|
|
-
Kwilasz AJ, Todd LS, Duran-Malle JC, Schrama AEW, Mitten EH, Larson TA, Clements MA, Harris KM, Litwiler ST, Wang X, Van Dam AM, Maier SF, Rice KC, Watkins LR, Barrientos RM. Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone. Behav Brain Res. 2021 01 01; 396:112896.
Score: 0.681
-
Zhang X, Peng Y, Grace PM, Metcalf MD, Kwilasz AJ, Wang Y, Zhang T, Wu S, Selfridge BR, Portoghese PS, Rice KC, Watkins LR, Hutchinson MR, Wang X. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling. FASEB J. 2019 08; 33(8):9577-9587.
Score: 0.156
-
Jewett DC, Klockars A, Smith TR, Brunton C, Head MA, Tham RL, Kwilasz AJ, Hahn TW, Wiebelhaus JM, Ewan EE, Carroll RM, Grace MK, Levine AS, Olszewski PK. Effects of opioid receptor ligands in rats trained to discriminate 22 from 2 hours of food deprivation suggest a lack of opioid involvement in eating for hunger. Behav Brain Res. 2020 02 17; 380:112369.
Score: 0.040
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|